支气管扩张药的全球市场:现状分析与预测(2021年～2027年)

全球支气管扩张药的市场规模，预计2021年～2027年最大记录5％的年复合成长率。

本报告提供全球支气管扩张药市场相关调查分析，市场规模与预测分析，主要趋势和机会，企业简介等资讯。

目录

第1章 市场简介

第2章 调查手法、前提条件

第3章 市场摘要

第4章 摘要整理

第5章 COVID-19对全球支气管扩张药市场影响

第6章 全球支气管扩张药市场收益(2019年～2027年)

第7章 市场考察:各适应症

• 气喘
• 慢性阻塞性肺病(COPD)
• 其他

第8章 市场考察:各药物类型

• β肾上腺素支气管扩张药
• 抗胆碱支气管扩张药
• 磷酸二酯酶抑制剂
• 配合药
• 其他

第9章 市场考察:各给药途径

• 口服
• 注射
• 吸入

第10章 市场考察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他的北美
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他的欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 其他的亚太地区
• 其他地区

第11章 支气管扩张药的市场动态

• 推动市场要素
• 市场课题
• 影响的分析

第12章 支气管扩张药市场机会

第13章 支气管扩张药市场趋势

第14章 政策和法规架构

第15章 需求端和供应端的分析

• 需求端分析
• 供应端分析

第16章 价值链分析

第17章 竞争模式

• 竞争情形
  • 波特的五力分析

第18章 企业简介

• Abbott Laboratories
• AstraZeneca plc.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline Plc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG.
• Pfizer Inc.
• SANOFI
• Teva Pharmaceutical Industries Ltd.
• Vectura Group Plc.

第19章 免责声明

Global Bronchodilators market is expected to register a CAGR of around ~5% over the period of 2021-2027. Bronchodilators are drugs that open up (dilate) the breathing passages by relaxing the bronchial smooth muscle. They make breathing easier for people with asthma or other lung conditions. Thus, the increase in the number of patients with respiratory disorders, and the treatment of various diseases such as asthma, chronic obstructive pulmonary disease, and others. The geriatric population is more vulnerable to respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC), in 2019, around 4,069,278 Americans aged above 65 years were living with asthma. Since bronchodilators play a vital role in maintaining optimal airflow within the lungs of these patients, this is likely to boost the demand for bronchodilators in near future. Moreover, the development of advanced bronchodilators by major companies and the diagnostics industry owing to the presence of well-established market players and frequent product launches in the region. For instance, in July 2020, EVA Pharma launched 'Inhalex', the first Egyptian medication for COPD with a 24-hour lasting effect. This product launch is projected to reduce the cost of the treatment of COPD patients to half.

Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG., Pfizer Inc., SANOFI, Teva Pharmaceutical Industries Ltd., Vectura Group Plc are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst indication, asthma category is expected to witness the highest CAGR during the forecast period"

Based on indication, the market is categorized into asthma, chronic obstructive pulmonary disease (COPD), and others. Among these, asthma is expected to witness the highest CAGR during the forecast period owing to the rising prevalence of asthma worldwide. For instance, as per World Health Organization (WHO) data, asthma affected around 262 million people in 2019 and triggered 461,000 deaths worldwide. In addition, the increase in the prevalence of pulmonary disorders is increasing the growth of the bronchodilators market.

"Amongst the drug type, anticholinergics bronchodilators are expected to highest CAGR during the forecast period"

Based on drug type, the market is categorized into beta-adrenergic bronchodilators, anticholinergic bronchodilators, phosphodiesterase inhibitors, combination drugs, and others. Among these, the anticholinergic bronchodilators are expected to witness the highest CAGR during the forecast period as it is available in both long-acting and short-acting forms. Anticholinergics act by inhibiting the effect of acetylcholine on airways and nasal passages. It is widely used to treat chronic obstructive pulmonary disease. According to, institute for Health Metrics and Evaluation (IHME), Chronic respiratory diseases were responsible for 71.1 million YLLs and 32.4 million YLDs in 2019. Chronic obstructive pulmonary disease (COPD) and asthma were the two largest contributors to the global respiratory disease burden.

"North America to significant share during the forecast period"

North America accounted for a prominent share of the global bronchodilators market and is expected to grow at a significant growth rate during the forecast period owing to the quick adoption of bronchodilators technologies along with the high incidence of COPD and asthma cases. The United States Environmental Protection Agency and the National Health Interview Surveys (NHIS), in April 2021, estimated that almost 25.1 million people, comprising 5.1 million children, have asthma in the country. In addition, Major healthcare companies are investing heavily in their products due to rising social awareness among healthcare industry experts, medical professionals, and patients about the benefits that bronchodilators have to prompt the regulatory authorities to consider and authorize the bronchodilators.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

Global Bronchodilators market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Limitation
• 1.3. Stakeholders
• 1.4. Currency used in Report

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Bronchodilators Market
• 2.2. Research Methodology of the Bronchodilators Market
• 2.3. Forecasting Method
• 2.4. Respondent Profile
• 2.5. Main Objective of the Bronchodilators Market Study

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL BRONCHODILATORS MARKET COVID-19 IMPACT

6 GLOBAL BRONCHODILATORS MARKET REVENUE (USD BN), 2019-2027F

7 MARKET INSIGHTS BY INDICATION

• 7.1. Asthma
• 7.2. Chronic obstructive pulmonary disease (COPD)
• 7.3. Others

8 MARKET INSIGHTS BY DRUG TYPE

• 8.1. Beta-Adrenergic Bronchodilators
• 8.2. Anticholinergic Bronchodilators
• 8.3. Phosphodiesterase Inhibitor
• 8.4. Combination Drugs
• 8.5. Others

9 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

• 9.1. Oral
• 9.2. Injection
• 9.3. Inhaler

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. UK
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. Rest of Asia-Pacific
• 10.4. Rest of World

11 BRONCHODILATORS MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 BRONCHODILATORS MARKET OPPORTUNITIES

13 BRONCHODILATORS MARKET TRENDS

14 POLICY & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. Abbott Laboratories
• 18.2. AstraZeneca plc.
• 18.3. Boehringer Ingelheim International GmbH
• 18.4. GlaxoSmithKline Plc.
• 18.5. F. Hoffmann-La Roche Ltd.
• 18.6. Novartis AG.
• 18.7. Pfizer Inc.
• 18.8. SANOFI
• 18.9. Teva Pharmaceutical Industries Ltd.
• 18.10. Vectura Group Plc.

19 DISCLAIMER